TLR9 and cancer: It is worth noting that when combined with poly(I:C) and CpG ODN for cancer treatment, these drugs should be adopted alternately, rather than together, to avoid the blocking effect of thiophosphate-modified TLR9 ligands and enhance proapoptotic effects [73].